Q-omics provides the consensus-scored TRMT61A profile across patient tissues and cancer cell-line models. TRMT61A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TRMT61A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TRMT61A protein abundance shows 24,293 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, HNSC, and LSCC as cancer lineages where TRMT61A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT61A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT61A survival associations across molecular data types. TRMT61A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT61A RNA expression–survival associations across cancer types. High TRMT61A expression shows unfavorable associations in ACC, LGG, LIHC, PRAD and CESC, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TRMT61A RNA expression.
This table summarizes TRMT61A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TRMT61A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT61A shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, STAD and CHOL. The HNSC box plot shows higher TRMT61A RNA expression in tumor versus normal tissue (log2 FC = +1.133, t-test p < 0.001).
This table shows molecular features associated with TRMT61A in patient tissues and cancer cell lines. In patient samples, TRMT61A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT61A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
